UPDATE: Morgan Stanley Starts Centessa Pharmaceuticals (CNTA) at Overweight

Centessa Pharmaceuticals (CNTA): Analysts Initiate With 'Buy' on 'Broad Pipeline With Significant Optionality'

Wall Street analysts have kicked off coverage of Centessa Pharmaceuticals (NASDAQ: CNTA) with a rating equivalent to Buy. So far, analysts at Jefferies, Goldman Sachs, and Morgan Stanley are all positive on the stock.

Centessa Pharmaceuticals secured $330 million in an initial public offering (IPO) in May in a bid to continue with its plan of reshaping the traditional drug development process.

The company initially intended to offer 15 million of its depositary shares in the IPO, priced between $18 and $20 per share. However, Contessa later raised the number of offered shares to 16.5 million,... More

Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy

Goldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $42.00.

The analyst comments "CNTA is an umbrella company reimagining the R&D model and leveraging asset centricity at scale (ten... More

UPDATE: Jefferies Starts Centessa Pharmaceuticals (CNTA) at Buy

(Updated - June 22, 2021 7:53 AM EDT)

Jefferies analyst Eun Yang initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $35.00.

The analyst commented, "As a holding company with 10 distinct subsidiaries, CNTA's broad pipeline in diverse therapeutic... More